Fennec Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Fennec Pharmaceuticals Inc FENC.OQ reported a quarterly adjusted loss of 4 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 47 cents. The mean expectation of five analysts for the quarter was for a loss of 9 cents per share. Wall Street expected results to range from -13 cents to -5 cents per share.

• Revenue fell 65.5% to $8.75 million from a year ago; analysts expected $8.18 million.

• Fennec Pharmaceuticals Inc's reported EPS for the quarter was a loss of 4 cents​.

• The company reported a quarterly loss of $1.17 million.

• Fennec Pharmaceuticals Inc shares had risen by 3.0% this quarter and lost 0.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 22.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc is $13.00

This summary was machine generated from LSEG data May 13 at 11:58 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)